Will President Trump’s Executive Order Lower Drug Prices?
Ultimately, assessing the impact of President Trump’s newest iteration of “Most Favored Nation” drug pricing depends on details that have yet to be fleshed out.
View the Latest: Prescription Drugs
Filter
-
-
Stand-Alone Drug Plans Cover a Larger Share of Medicare Part D Enrollees Living in the Most Rural Areas Than Medicare Advantage Plans
Issue BriefTo understand the role of Medicare Part D stand-alone prescription drug plans in serving rural Medicare beneficiaries, this data note analyzes 2025 Part D enrollment in PDPs and Medicare Advantage drug plans by geographic area nationally and at the state level.
-
The Effect of Delaying the Selection of Small Molecule Drugs for Medicare Drug Price Negotiation
Policy WatchIn a new Trump administration executive order, the Secretary of HHS is directed to work with Congress to implement a change in law to delay negotiation of so-called “small molecule” drugs under the Inflation Reduction Act's Medicare Drug Price Negotiation Program for an additional 4 years. This brief analyzes how many of the drugs previously selected for negotiation would not have been eligible if this policy had been in place at the time.
-
Health Spending Issues to Watch This Year
Issue BriefKFF and the Peterson Center on Healthcare examine market trends contributing to rising health costs and identify several potential federal and state policy issues to watch throughout 2025, including high-cost drugs, federal funding cuts, and workforce shortages.
-
Classifying Misoprostol and Mifepristone as Controlled Substances: Implications for the Management of Non-Abortion Related Conditions
Issue BriefThis data note analyzes employer-sponsored insurance and Medicaid claims data to see how mifepristone and misoprostol—two drugs used in the medication abortion regimen—are prescribed for reasons other than abortion including management of miscarriages, abnormal bleeding or hemorrhage, as well as IUD insertions and other conditions.
-
Skepticism Surrounding ADHD Diagnoses and Medication — The Monitor
FeatureThis volume examines the impact of recent executive actions on federal health communication, along with concerns and stigmas surrounding ADHD diagnoses and treatments, including skepticism about pharmaceutical influence on medication promotion. It also explores distrust in food regulations following the FDA’s ban on Red Dye No. 3.
-
KFF Prescription Drug Advertisements Poll: January 2025
Poll FindingKFF’s January 2025 Prescription Drug Advertisements Poll looks at the public's experiences with prescription drug advertisements, whether they've talked to a doctor about advertised drugs, and how this has influenced the care they receive.
-
FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program
Issue BriefThe Centers for Medicare & Medicaid Services (CMS) recently announced the drugs selected for the second round of negotiation for the Medicare Drug Price Negotiation Program, which was established by the Inflation Reduction Act. These FAQs address several questions related to Medicare’s drug price negotiation program and CMS's implementation of the program, with a focus on the details that apply for 2027, the second year that negotiated prices will be available under the program.
-
KFF Health Tracking Poll: Public Weighs Health Care Spending and Other Priorities for Incoming Administration
FeatureWith the incoming Trump administration and Republican-led Congress looking to ways to reduce federal spending, this Poll finds that the Medicare and Medicaid programs remain broadly popular, and more people favor more spending on those programs than less spending. Among potential actions on health, the public sees price transparency and limiting chemicals in food as top priorities. Few say so about cuts to Medicaid and restrictions on abortion.
-
Ozempic’s Selection for Medicare Drug Price Negotiation Could Raise the Stakes for the Negotiation Program
Quick TakeSemaglutide…has been selected for the second round of Medicare drug price negotiation…Many people are familiar with Ozempic and other drugs like it, use of these drugs has expanded rapidly in recent years, and the list price is high. All of that could focus more attention on this year’s drug price negotiation process….